Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)

v3.3.1.900
Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Jan. 31, 2014
USD ($)
Nov. 30, 2008
USD ($)
Product
Dec. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
License and collaborative fees         $ 49,064,000 $ 5,683,000 $ 11,028,000
Novartis [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment received       $ 37,000,000      
Performance deliverable period for license and regulatory services         90 days    
Performance deliverable period for transfer of materials, process and knowhow         90 days    
Performance deliverables value on stand alone basis         $ 0    
Novartis [Member] | Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Future milestone payments, maximum     $ 14,000,000        
Collaborative Arrangement [Member] | Novartis [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Proceeds from collaborators     6,200,000        
Reduction in debt under restructured agreement     $ 7,500,000        
Royalty right expiration period     20 years        
Milestone received under the collaboration agreement $ 0           $ 7,000,000
Repayment of debt   $ 1,750,000          
Percentage of milestone received   25.00%          
License and collaborative fees         0 $ 0  
Maximum borrowing capacity under loan agreement $ 50,000,000     $ 50,000,000 $ 50,000,000    
Research and development expenses funded through loan facility, maximum (in hundredths)         75.00%    
Upfront payment received         $ 37,000,000    
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones         $ 480,000,000    
Collaborative Arrangement [Member] | Novartis [Member] | Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Number of ongoing product programs with potential royalty right milestone payments | Product     2